Company / Current Liabilities
Protalix BioTherapeutics, Inc. Current Liabilities History
FY2015-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities
$26.5M
FY2025
5-year range
$25.6M / $45.5M
FY2021-FY2025
Trend
+3.5%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Current Liabilities has fluctuated over the past 10 years, ranging from $11M in FY2015 to $86M in FY2020.
Based on SEC 10-K filings.
$27M in FY2025 with a 10-year CAGR of +9.0%.
Improved from $46M to $27M over the past 2 years.
Current Liabilities over time
Growth rates
- 3-Year CAGR
- -6.5%
- 5-Year CAGR
- -21.1%
- 10-Year CAGR
- +9.0%
Key checks
Key Insights
- 5-year CAGR of -21.1%, indicating a declining trend.
- In FY2025, current liabilities increased 3.5% year-over-year.
- Peak current liabilities was recorded in FY2020.
- Lowest current liabilities in the period was in FY2015.
Company context
Key Data Points
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current LiabilitiesValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $26.5M | +3.5% |
| FY2024 | $25.6M | -43.7% |
| FY2023 | $45.5M | +40.4% |
| FY2022 | $32.4M | -2.3% |
| FY2021 | $33.2M | -61.6% |
| FY2020 | $86.5M | +115.2% |
| FY2019 | $40.2M | +76.6% |
| FY2017 | $22.8M | -65.6% |
| FY2016 | $66.2M | +489.3% |
| FY2015 | $11.2M | -57.1% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026